ST2 in Pulmonary Disease

Ednan K Bajwa; Alexandre Mebazaa; James L Januzzi

doi:10.1016/j.amjcard.2015.01.040

ST2 in Pulmonary Disease

Am J Cardiol. 2015 Apr 2;115(7 Suppl):44B-7B. doi: 10.1016/j.amjcard.2015.01.040. Epub 2015 Jan 23.

Authors

Ednan K Bajwa¹, Alexandre Mebazaa², James L Januzzi³

Affiliations

¹ Pulmonary and Critical Care Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: ebajwa@mgh.harvard.edu.
² Department of Anesthesiology and Critical Care Medicine, University of Paris Diderot, Paris, France.
³ Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

PMID: 25665765
DOI: 10.1016/j.amjcard.2015.01.040

Abstract

In recent years, numerous studies have focused on the use of soluble ST2 (sST2) as a clinical biomarker for cardiovascular disease. However, much preclinical data points to involvement of the ST2 pathway in inflammation, and specifically in pulmonary inflammation. This report summarizes the current body of clinical data suggesting the potential role of the ST2 pathway in clinical disease, including evidence that sST2 could be a useful biomarker in both allergic and nonallergic pulmonary disease.

Publication types

Review

MeSH terms

Biomarkers / blood
Humans
Interleukin-1 Receptor-Like 1 Protein
Lung Diseases / blood*
Receptors, Cell Surface / blood*

Substances

Biomarkers
IL1RL1 protein, human
Interleukin-1 Receptor-Like 1 Protein
Receptors, Cell Surface